Skip to main content

Table 3 Estimated treatment effect for each outcome relative to fluconazole (sensitivity analysis using an empirical prior)

From: Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients

Comparator Median posterior odds-ratio relative to fluconazole
(interquartile range)a
Posterior probability of having lower incidence than fluconazole Posterior probability of having the lowest incidence of all treatments
Proven/probable IFI at 180 days
Fluconazole 0%
Itraconazole 0.54 (0.42–0.67) 95% 27%
Posaconazole 0.57 (0.41–0.76) 88% 29%
Voriconazole 0.47 (0.36–0.63) 95% 44%
Proven/probable IA at 180 days
Fluconazole 0%
Itraconazole 0.68 (0.53–0.90) 82% 4%
Posaconazole 0.30 (0.20–0.45) 96% 59%
Voriconazole 0.37 (0.26–0.54) 96% 36%
Proven IC at 180 days
Fluconazole 2%
Itraconazole 0.31 (0.19–0.49) 95% 71%
Posaconazole 0.97 (0.49–1.96) 51% 16%
Voriconazole 0.90 (0.49–1.69) 55% 12%
All-cause mortality
Fluconazole 22%
Itraconazole 1.18 (1.03–1.34) 21% 7%
Posaconazole 0.98 (0.82–1.16) 54% 41%
Voriconazole 1.01 (0.88–1.17) 48% 30%
OLAT use at 180 days
Fluconazole 3%
Itraconazole 0.95 (0.78–1.14) 58% 7%
Posaconazole 1.07 (0.83–1.37) 43% 12%
Voriconazole 0.64 (0.54–0.75) 94% 79%
  1. IFI, invasive fungal infections; IA, invasive aspergillosis; IC, invasive candidiasis; OLAT, other licensed antifungal therapy.
  2. aEstimates less than zero indicate a reduced probability of proven/probable IFI at 180 days relative to fluconazole.